Padeliporfin
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
Padeliporfin: From an Undocumented Original Indication to Clear Cell Renal Carcinoma
One-Sentence Summary
Padeliporfin (WST-11) is a vascular-targeted photosensitizer used in photodynamic therapy (VTP); this evidence pack does not contain a confirmed original indication or approved labelling for it. The TxGNN model predicts it may be effective for Clear Cell Renal Carcinoma, but this is currently supported only by 2 preclinical (animal) publications and no registered clinical trials.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not available — no marketing licences or approved indication text in this evidence pack |
| Predicted New Indication | Clear Cell Renal Carcinoma |
| TxGNN Prediction Score | 98.75% |
| Evidence Level | L4 (preclinical/mechanism studies only) |
| Denmark Market Status | Not Marketed |
| Number of Marketing Authorisations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism-of-action data for Padeliporfin is flagged as a data gap (DG002) in this evidence pack, and no formal original indication is recorded. However, the supporting literature itself describes Padeliporfin (WST-11) as a bacteriochlorophyll-derived, vascular-acting photosensitizer used in Vascular Targeted Photodynamic Therapy (VTP): upon laser activation it causes rapid, localized vascular occlusion and necrosis of the illuminated tissue.
The rationale for extending this technology to clear cell renal carcinoma comes from PMID 29344301, which used a mouse RENCA (renal adenocarcinoma) model and observed a >60% drop in tumor oxygen saturation within one hour of VTP treatment — evidence that the mechanism can act on renal tumor vasculature. A related study (PMID 26860792) demonstrated similar vascular-targeted ablation activity against urothelial tumors of the upper urinary tract in porcine and mouse models, reinforcing that the technology is mechanistically active within the renal/urinary anatomical region.
Important caveats: the RENCA model is a renal adenocarcinoma model, not histologically identical to human clear cell RCC; both supporting studies are animal-only (Tier 3/preclinical), with no human pharmacokinetic, safety, or efficacy data, and no clinical trials have been registered for this indication.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 29344301 | 2018 | Preclinical (Animal, mouse RENCA model) | Theranostics | Multispectral optoacoustic tomography monitored WST-11 VTP effects in a renal cell cancer mouse model; treatment produced measurable tumor vascular/oxygenation changes |
| 26860792 | 2016 | Preclinical (Animal, porcine + mouse xenograft) | The Journal of Urology | Endoluminal WST-11 VTP ablated ureter/renal pelvis urothelial tumor tissue in swine and mouse models, suggesting technical feasibility for kidney-adjacent tumors |
Denmark Market Information
Padeliporfin currently has no marketing authorisations recorded in this evidence pack (0 licences; market status: Not Marketed).
Safety Considerations
Please refer to the approved Summary of Product Characteristics (SmPC) for safety information — none is currently available, as Padeliporfin is not marketed in Denmark and TFDA label/warning data is flagged as a Blocking data gap (DG001) in this evidence pack. A drug-drug interaction (DDI) search returned no results (not found).
Conclusion and Next Steps
Decision: Hold
Rationale: Evidence is currently limited to two preclinical animal studies (Evidence Level L4) with no clinical trials, no confirmed mechanism-of-action data, and a Blocking data gap on safety/labelling (DG001) that prevents even an initial safety screen (S1). The drug is also not marketed in Denmark.
To proceed, the following is needed:
- TFDA/SmPC warnings, contraindications, and safety data (DG001, Blocking)
- Confirmed mechanism of action and formal original indication (DG002, High)
- Preclinical or clinical data specific to clear cell renal carcinoma (current evidence uses a RENCA model, not confirmed clear cell histology)
- Registered clinical trial or at minimum a formal nonclinical development plan before any human-use evaluation
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.